Therapy-related B-lymphoblastic leukemia after multiple myeloma.

Authors :: Kallen ME
Koka R
Singh ZN
Ning Y
Kocoglu MH
Badros AZ
Niyongere S
Duong VH
Emadi A
Baer MR
Source :: Leukemia research reports [Leuk Res Rep] 2022 Nov 01; Vol. 18, pp. 100358. Date of Electronic Publication: 2022 Nov 01 (Print Publication: 2022).
Publication Year :: 2022
Abstract: New therapies for multiple myeloma have improved outcomes, but are associated with therapy-related hematologic malignancies. We report eight patients with therapy-related B-lymphoblastic leukemias (t-B-ALL) in the setting of therapy for multiple myeloma, which included lenalidomide maintenance. A subset of patients had pancytopenia and low-level marrow involvement by acute leukemia, an unusual finding in de novo B-ALL. One patient died of chemotherapy complications; the other seven responded. No patient died of B-ALL (median follow up of 1.0 years). Our series suggests that t-B-ALL is clonally unrelated to myeloma, presents with diverse cytogenetic abnormalities, and responds well to B-ALL therapy.<br />Competing Interests: The authors have no conflicts of interest to disclose.<br /> (© 2022 The Author(s).)